PriceTargets.com logo

LON:FARN - Faron Pharmaceuticals Oy Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 215 As of 06/30/2022 01:00 AM ET
+0.30 (1.20%)

This chart shows the closing price for FARN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Faron Pharmaceuticals Oy Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FARN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FARN

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Faron Pharmaceuticals Oy in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of GBX 0. The average price target represents a -100.00% upside from the last price of GBX 215.

This chart shows the closing price for FARN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Faron Pharmaceuticals Oy. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/31/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/7/2020Panmure GordonReiterated RatingUnder Review
10/2/2017Panmure GordonReiterated RatingBuy
9/6/2017Panmure GordonReiterated RatingBuyGBX 723
8/30/2017Panmure GordonReiterated RatingBuy
(Data available from 6/30/2017 forward)

News Sentiment Rating

0.42 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/2/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/1/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/31/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
3/2/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/1/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/1/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/31/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/30/2022

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Faron Pharmaceuticals Oy logo
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. The company also develops Haematokine, a new chemical entity AOC3 inhibitor for the treatment of hematological malignancies and bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.
Read More

Today's Range

Now: GBX 215
Low: 202
High: 215

50 Day Range

MA: GBX 223.27
Low: 200
High: 240

52 Week Range

Now: GBX 215
Low: 200
High: 495

Volume

6,532 shs

Average Volume

19,768 shs

Market Capitalization

£114.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Faron Pharmaceuticals Oy?

The following Wall Street analysts have issued reports on Faron Pharmaceuticals Oy in the last year:
View the latest analyst ratings for FARN.

What is the current price target for Faron Pharmaceuticals Oy?

0 Wall Street analysts have set twelve-month price targets for Faron Pharmaceuticals Oy in the last year.
View the latest price targets for FARN.

What is the current consensus analyst rating for Faron Pharmaceuticals Oy?

Faron Pharmaceuticals Oy currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for FARN.

How do I contact Faron Pharmaceuticals Oy's investor relations team?

Faron Pharmaceuticals Oy's physical mailing address is Intelligate, Joukahaisenkatu 6, TURKU, 20520, Finland. The company's listed phone number is +358-2-4695151. The official website for Faron Pharmaceuticals Oy is www.faron.com. Learn More about contacing Faron Pharmaceuticals Oy investor relations.